Valeant Wins Battle for Salix Pharmaceuticals

The Wall Street Journal

Valeant Wins Battle for Salix Pharmaceuticals

Cahill advised the financing sources in their various capacities as initial purchasers, underwriters, agents and lead arrangers in debt, equity and bank financing transactions that backed the $15.8 billion acquisition of Salix Pharmaceuticals by Valeant Pharmaceuticals. The deal was consummated in a relatively compressed time frame and Cahill represented Deutsche Bank Securities, HSBC, MUFG, DNB Markets, SunTrust Robinson Humphrey, Barclays, Morgan Stanley, RBC Capital Markets and Citigroup in providing committed financing for the acquisition as well as each of the three distinct bank, bond and equity transactions that collectively generated proceeds of over $16.5 billion to fund the acquisition.